BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221.5 USD | -0.56% |
|
+1.83% | -14.40% |
| 05-09 | MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman | RE |
| 05-08 | Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating | MT |
ETFs positioned on Biogen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | -0.73% | - | |
| 0.03% | 1 M€ | +3.03% | - | |
| 0.03% | 15 M€ | -1.62% | - | |
| 0.03% | 0 M€ | +3.50% | - | |
| 0.03% | 7 M€ | +0.11% | - | |
| 0.03% | 6 M€ | +3.89% | ||
| 0.02% | 0 M€ | +2.80% | - | |
| 0.02% | 0 M€ | +11.98% | - | |
| 0.01% | 0 M€ | +0.32% | - | |
| 0.01% | 0 M€ | +0.50% | - | |
| 0.01% | 0 M€ | +2.72% | - | |
| 0.01% | 6 M€ | -4.26% | - | |
| 0.01% | 0 M€ | +3.95% | - | |
| 0.00% | 0 M€ | +3.63% | - | |
| 3.88% | 0 M€ | +6.50% | - | |
| 4.33% | 0 M€ | +4.75% | - |
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
221.5
USD
Average target price
285.9
USD
Spread / Average Target
+29.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.40% | 32.25B | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B | |
| -3.16% | 8.62B |
- Stock Market
- Equities
- BIIB Stock
- Funds and ETFs Biogen Inc.